MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate various intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Main demo targets were to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst among the list of exploratory https://angeloiviuh.blogadvize.com/37828572/not-known-details-about-ceftriaxone